Lucia Ansani

Italian Multicenter Study on a Single Lead VDD Pacing System Using a Narrow Atrial Dipole Spacing

Since November 1988, 514 patients with advanced atrioventricular (AV) block and normal sinoatrial function have received the single lead VDD pacing system Twinal 30 Lem/CCS in 30 Italian centers. At implantation, particular attention was paid to the correct positioning of the atrial dipole in the mid‐ to mid‐high right atrium and to the atrial electrogram characteristics. The follow‐up included a chest X ray, to be performed before discharge of the patient from the hospital, telemetric evaluations of the endoatrial potential, provocative tests for interferences by myopotentials, 24‐hour ambulatory EGG recordings, and where possible, exercise stress tests. The mean follow‐up duration was 15.2 months, ranging from 1 to 42 months. A very low percentage of chronic atrial fibrillation, loss of atrial sensing, and system replacement was reported, most of the patients (93.5%) being paced in VDD mode. All investigations indicated an excellent overall system performance, stable AV synchrony, and infrequent myopotential interference, and a low complication rate throughout the follow‐up period.

Long‐Term Reliability of Single Lead Atrial Synchronous Pacing Systems Using Closely Spaced Atrial Dipoles: Five‐Year Experience

To assess the long‐term capability of single atrioven ticular (AV) lead VDD pacing systems using close atrial dipoles to assure reliable atrial guided pacing, the safety and efficacy of 86 VDD units implanted in 73 patients at a single center since November 1988 was reviewed. All patients suffered from advanced AV block with normal sinoatrial function. Sixty five patients received a LEM/CCS Twinal 30/30S system, four patients received a Vitatron‐Saphir system, and four patients received a Medtronic Thera VDR 8348 system. All patients underwent provocative tests in search of myopotential interference, and Holter recordings; in a group of patients who underwent pacemaker replacement a comparison was made between implant and replacement measurements. The mean follow‐up duration was 27.3 months. A high percentage of successfully VDD paced patients and a low incidence of pacemaker malfunction, regularly solved by pacemaker reprogramming, was reported. Atrial signal amplitudes comparable to those measured at implant were found at replacement in all patients. These data support the long‐term reliability of single AV lead VDD pacing systems with closely spaced atrial dipoles, as well as stable atrial sensing by floating bipolar atrial electrodes and effective atrial synchronous ventricular pacing over time.

AV delay optimization and management of DDD paced patients with dilated cardiomyopathy.

Ten DDD paced patients, suffering front dilated cardiomyopathy in the NYHA functional classes III or IV were studied by means of Doppler ecbocardiography at different programmed values of atrioventricular (AV) delay (200, 150, 120, 100, and 80 msec). The following variables were evaluated: LV diameter, ejection fraction, mitral and aortic flow velocity integrals, and stroke volume. During VDD pacing, a resting AV delay associated with the best diastolic filling and systolic function was identified and programmed individually. Shortening of the AV delay to about 100 msec was associated with a gradual and progressive improvement. Further decrease caused an impairment of systolic function. The patients were clinically and beinodynamically reevaluated after 2 months of follow‐up. A reduction of NYHA class and an improvement of LV function were consistently found. The reported data suggest that programming of an optimal A V delay may improve myocardial function in DDD paced patients with congestive heart failure. This result may be the consequence of an optimization of left ventricular filling and a better use of the Frank‐Starling law.

A New Single Lead VDD Pacing System

PERCOCO, G.F., ET AL.: A New Single Lead VDD Pacing System. In 24 patients with advanced heart block and normal sinus node function, a new single lead VDD pacing system was implanted. At implantation, the endoatrial, bipolar electrogram was recorded in all patients. The lead position was checked by means of chest X‐ray. At discharge and after 1, 3, and 6 months, testing for myopotential inhibition, telemetric evaluation of the endoatrial potential, and Holter recordings were made. After discharge, 18 patients performed two cardiopulmonary exercise tests at two different rate‐matched AV intervals. All investigations showed good AV synchrony and a lack of interferences by myopotentials. The maximum rate‐matched AV interval provided a significantly improved exercise capacity, which was more evident in patients with signs of myocardial failure.

High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients.

AbstractBackground: Primary bare metal stenting and abciximab infusion are currently considered the best available reperfusion strategy for acute ST-segment elevation myocardial infarction (STEMI). Sirolimus eluting stents (SES), compared to bare metal stent (BMS), greatly reduce the incidence of binary restenosis and target vessel revascularisation (TVR), but their use on a routine basis results in a significant increase in medical costs. With current European list prices, the use of tirofiban instead of abciximab would save enough money to absorb the difference between SES and BMS. Aim: To assess whether in patients with STEMI the combination of SES with high dose bolus (HDB) tirofiban results in a similar incidence of major cardiovascular events (MACE) but in a lower binary restenosis rate after six months compared to BMS and abciximab. Methods and Results: 160 patients are required to satisfy the primary composite end-point, including MACE and binary restenosis. The study is ongoing: the current paper focuses on the methodology and demography of the first 100 patients so far enrolled. Patients randomised to HDB tirofiban (n = 50, mean age: 62 ± 12, 40 males) and abciximab (n = 50, mean age: 63 ± 12, 38 males) do not differ for medical history, presentation profile, medications at discharge, angiographic profile and creatine-kinase MB-fraction at peak. Conclusions: The results of the trial will be available by the end of 2004: they will be crucial for the cardiologists to know whether the gold standard for AMI treatment should be reconsidered after the introduction of SES into the clinical practice.

AV Delay and Exercise Stress Tests: Behavior in Normal Subjects

BARBIERI, D., ET AL.: AV Delay and Exercise Stress Tests: Behavior in Normal Subjects. In normal subjects the atrioventricular (AV) conduction is accelerated during exertion. The relationship between heart rate and AV delay is usually described as “linear”. Looking at the increasing importance given to an appropriate AV synchrony in permanent dual chamber and P synchronous pacing we present the results of an investigation performed to study the correlation between AV conduction time and heart rate under stress conditions, and disclose some new aspects of this matter, which will possibly be useful for a further improvement of pacemaker technology.

Effect of ibopamine on peripheral haemodynamics

SummaryPeripheral haemodynamics was studied in healthy volunteers by strain gauge plethysmography after administration of ibopamine (IB), diisobutyric ester of N-methyl-dopamine, an orally active dopaminergic agonist. Seven subjects received a single oral dose of ibopamine of 150 mg and 6 received a daily dose of 150 mg (50 mg t.i.d.) for 5 consecutive days. Arterial resting blood flow and venous capacity increased and peripheral resistance decreased significantly. Six further subjects were then studied; 3 h after an oral dose of ibopamine 150 mg, the parenteral administration of Sulpiride 50 mg, a specific vascular dopaminergic antagonist, was found significantly to counteract its peripheral activity. Heart rate and arterial blood pressure were never affected and tolerability was good.

The effect of captopril on peripheral hemodynamics in patients with esential hypertension: Comparison between oral and sublingual administration

SummaryA comparative study of the effects of oral and sublingual captopril on the hemodynamics of the peripheral musculocutaneous vasculature was carried out on ten patients with essential hypertension. Both routes of administration of captopril lead to lower blood pressure and decreased regional resistance, and to an increased arterial blood flow at rest. The first measurable effect and the peak effect on blood pressure and peripheral hemodynamics appear slightly earlier with sublingual administration. The data provided in this study support the usefulness of the sublingual route in clinical situations in which oral administration of captopril is not feasible.

Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study

SummaryUnder double-blind conditions, 150 mg of ibopamine (di-isobutiric ester of N-methyldopamine) or placebo were given orally to 11 patients with congestive heart failure; after 3 hours, 50 mg of sulpiride were administered intramuscularly. Peripheral hemodynamics were evaluated at the level of the forearm using strain-gauge plethysmography. Ibopamine increased arterial blood flow and venous capacity and decreased arterial peripheral resistance; these effects were counteracted by sulpiride. No significant changes were observed after placebo and sulpiride. These findings confirm the vasodilating effects of ibopamine on peripheral hemodynamics and its utility in patients for the treatment of congestive heart failure.

Single Lead VDD pacing: an update

A widespread use of P-synchronous pacing became possible in the mid to late 1970s, although that system was available from the early 1960s as VAT mode [1]; at that time, in fact, this mode of pacing required two leads, one to sense atrial depolarization and the other to pace the ventricle, but the insertion of two leads through a single vein was very difficult because of the limited lead technology. The development of a system able to assure a reliable AV synchrony via a single AV lead would have been the ideal solution to the problems of implant, simplifying the venous approach and representing a suitable treatment for patients with complete AV block (CHB) and normal sinoatrial function (SAF) who do not require atrial pacing.